Trial Profile
A Phase I, Multicenter, Open-label, Single-dose Study to Assess the Pharmacokinetics of MEK162 in Subjects With Mild, Moderate and Severe Hepatic Impairment
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 01 Mar 2023
Price :
$35
*
At a glance
- Drugs Binimetinib (Primary)
- Indications Acute myeloid leukaemia; Biliary cancer; Breast cancer; Cancer; Chronic myeloid leukaemia; Colorectal cancer; Fallopian tube cancer; Gastrointestinal stromal tumours; Glioma; Haematological malignancies; Malignant melanoma; Multiple myeloma; Neurofibromatosis 1; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Solid tumours; Uveal melanoma
- Focus Pharmacokinetics
- Sponsors Array BioPharma; Novartis
- 17 Sep 2021 Results assessing the effect of hepatic impairment on the pharmacokinetics, safety, and tolerability of Binimetinib in subjects with hepatic impairment, presented at the 2021 American College of Clinical Pharmacology Annual Meeting.
- 09 Mar 2017 Status changed from recruiting to discontinued.
- 30 Jan 2017 Planned primary completion date changed from 1 Nov 2016 to 31 Mar 2017.